Before the Open (Oct 9)

Good morning. Happy Tuesday.
The Asian/Pacific markets closed mostly down. Indonesia did well, but Japan, South Korea, India, New Zealand and Australia were weak. Europe, Africa and the Middle East currently lean to the downside. Denmark, Germany, Greece, Finland, Switzerland and Sweden are weak. Futures in the States point towards a relatively big gap down open for the cash market.
—————
Webinar: Today, October 9: Finding Your Sweet Spot With MACD and Stochastic
—————
The dollar is up. Oil is up; copper is down. Gold and silver are mixed and little changed. Bonds are mixed and little changed.
Overnight Stock Movers from barchart.com…
Apple (AAPL -0.23%) was rated a new ‘Sell’ at Vertical Group with a price target of $175.
Mohawk Industries (MHK +0.75%) was downgraded to ‘Underweight’ from ‘Neutral’ at JPMorgan Chase with a price target of $160.
PayPal Holdings (PYPL -3.16%) was upgraded to ‘Buy’ from ‘Hold’ at DZ Bank AG with a price target of $90.
Tesla (TSLA -4.35%) was rated a new ‘Outperform’ at Macquarie with a price target of $430.
Merk & Co (MRK +0.61%) was rated a new ‘Buy’ at Guggenheim Securities with a price target of $84.
Twilio (TWLO -3.30%) was rated a new ‘Buy’ at Deutsche Bank with a price target of $88.
PPG Industries (PPG +1.44%) fell more than 10% in after-hours trading after it reported preliminary Q3 adjusted EPS from continuing operations would be $1.41-$1.45, weaker than consensus of $1.59.
Blackbaud (BLKB -3.76%) tumbled 13% in after-hours trading after it cut its full-year adjusted EPS estimate to $2.46-$$2.52 from a previous estimate of $2.75-$2.88, well below consensus of $2.78.
Arcus Biosciences (RCUS -6.94%) was rated a new ‘Outperform’ at Wedbush with a price target of $22.
Yext (YEXT -3.33%) was rated new ‘Buy’ at D.A. Davidson with a price target of $28.
Cision Ltd (CISN -1.36%) lost 2% in after-hours trading after it was downgraded to ‘Hold’ from ‘Buy’ at Deutsche Bank.
Affimed NV (AFMD +10.77%) plunged 23% in after-hours trading after a Phase 1 program to evaluate its AFM11 drug for treatment of patients with relapsed or refractory CD19 positive B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemia was put on hold after serious adverse events happened in three patients who were in the trial.
Today’s Economic Calendar
6:00 NFIB Small Business Optimism Index
8:55 Redbook Chain Store Sales
10:00 Fed’s Evans Speech
9:15 PM Fed’s Williams: Monetary Policy
Other…
today’s upgrades/downgrades from briefing.com
this week’s Earnings from Morningstar
this week’s Economic Numbers/Reports powered by ECONODAY